Newark, New Jersey – January 26, 2023 – BioCentriq, Inc.—a New Jersey-based, cell and gene therapy contract development and manufacturing organization (CDMO)—announced today that they’ve completed a study designed to test transfection of T-cells with GFP mRNA for evaluation of cell viability, transfection efficiency, and post transfection growth using Kytopen’s Flowfect® technology. [Read more…]
Athersys Provides MultiStem Clinical Update
Enrollment completed in second cohort of MATRICS-1 trial in hemorrhagic trauma
Enrollment reaches halfway mark in MASTERS-2 trial in ischemic stroke
CLEVELAND–Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the treatment of ischemic stroke (MASTERS-2). MultiStem is a proprietary off-the-shelf stem cell product in late-stage clinical trials for acute ischemic stroke, as well as trauma and other inflammatory conditions. [Read more…]
CooperSurgical® Announces More than 11,000 Families Have Enrolled in Newborn Possibilities Program®
Program provides free cord blood and tissue processing to qualifying families in need.
TRUMBULL, Conn., Jan. 5, 2023 — CooperSurgical, a global leader in fertility and women’s health, shared that more than 11,000 families have enrolled in the Newborn Possibilities Program® through their Cord Blood Registry® (CBR®) brand. Through the Newborn Possibilities Program, CBR offers free cord blood and tissue processing and five years of storage for families with a qualifying medical need. [Read more…]
BioCentriq Announces Successful Tech Transfer From Avenge Bio for Manufacturing of Drug Product AVB-001 Resulting in Dosing of First Patient in Phase 1/2 Clinical Trial
Newark, New Jersey, January 17, 2022 – BioCentriq, Inc.—a New Jersey-based, cell and gene therapy contract development and manufacturing organization (CDMO)—announced today that they have successfully completed tech transfer of AVB-001 from client Avenge Bio and initiated manufacturing of clinical grade material, which will support Avenge Bio’s ongoing phase 1/2 clinical trial.
Sernova and Evotec on Track to Initiate Clinical Testing of First iPSC-Derived Islets as a Potential Functional Cure for Type 1 Diabetes
-
First iPSC-derived commercially viable off-the-shelf islet combination product is advancing towards regulatory filing in 2024 for anticipated clinical trial authorization to treat patients with Type 1 Diabetes (T1D) and severe hypoglycemia
-
iPSC islet-like cluster manufacturing scale-up and tech transfer activities are well under way in preparation for first human clinical evaluation
-
T1D preclinical models with iPSC derived islet clusters transplanted in Sernova’s Cell Pouch has now demonstrated consistent long-term insulin independence de-risking the combined technologies for both companies
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 96
- Next Page »